Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer.
Standard
Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. / Solbach, Christine; Roller, Marc; Ahr, Andre; Loibl, Sibylle; Nicoletti, Maria; Stegmueller, Manfred; Kreysch, Hans-Georg; Knecht, Rainald; Kaufmann, Manfred.
In: INT J CANCER, Vol. 101, No. 4, 4, 2002, p. 390-394.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer.
AU - Solbach, Christine
AU - Roller, Marc
AU - Ahr, Andre
AU - Loibl, Sibylle
AU - Nicoletti, Maria
AU - Stegmueller, Manfred
AU - Kreysch, Hans-Georg
AU - Knecht, Rainald
AU - Kaufmann, Manfred
PY - 2002
Y1 - 2002
N2 - Recent studies demonstrated that tumors overexpressing the epidermal growth factor receptor (EGF-R, erbB-1) are associated with poor clinical outcome. This led to the development of a variety of monoclonal antibodies targeting the extracellular domain of this receptor tyrosine kinase. The aim of our study was the evaluation of anti-EGF-R antibody EMD 55900 therapy for treatment of breast cancer. On the basis of 299 tumor specimens derived from breast cancer patients, we investigated EGF-R expression and generated a collective of primary xenotransplants in athymic nude mice. The animals received therapy in 2 treatment schedules to investigate the therapeutic response in early stages of tumor formation as well as on well established tumors. Using 6 different tumors with EGF-R expression levels between 10-300 fmol/mg total protein, we found a therapeutic effect when the EGF-R expression of the tumors was at least 40 fMol/mg. On the basis of these experimental data and our EGF-R expression analysis of breast cancer specimens, we conclude that up to 15% of breast cancer patients could benefit from this monotherapy with EMD 55900.
AB - Recent studies demonstrated that tumors overexpressing the epidermal growth factor receptor (EGF-R, erbB-1) are associated with poor clinical outcome. This led to the development of a variety of monoclonal antibodies targeting the extracellular domain of this receptor tyrosine kinase. The aim of our study was the evaluation of anti-EGF-R antibody EMD 55900 therapy for treatment of breast cancer. On the basis of 299 tumor specimens derived from breast cancer patients, we investigated EGF-R expression and generated a collective of primary xenotransplants in athymic nude mice. The animals received therapy in 2 treatment schedules to investigate the therapeutic response in early stages of tumor formation as well as on well established tumors. Using 6 different tumors with EGF-R expression levels between 10-300 fmol/mg total protein, we found a therapeutic effect when the EGF-R expression of the tumors was at least 40 fMol/mg. On the basis of these experimental data and our EGF-R expression analysis of breast cancer specimens, we conclude that up to 15% of breast cancer patients could benefit from this monotherapy with EMD 55900.
M3 - SCORING: Zeitschriftenaufsatz
VL - 101
SP - 390
EP - 394
JO - INT J CANCER
JF - INT J CANCER
SN - 0020-7136
IS - 4
M1 - 4
ER -
